Induction of multilineage markers in human myeloma cells and their down-regulation by interleukin 6.
Human primary myeloma cells are well known to be heterogeneous with regard to morphology and surface phenotype. We confirmed the heterogeneous expression of such multilineage markers as CD33, CD7, CD56, CD4, and CD86 in primary myeloma cells from 20 patients with multiple myeloma and in 8 human myeloma cell lines. CD33 expression in the Liu01 cell line, a subclone of U266 cells, and in vitamin D3-treated ILKM3 cells, correlated with a monocytoid morphology featuring convoluted nuclei and with increased C/EBPalpha expression. CD56+ myeloma cells from some myeloma patients and the CD56+ (but not the CD56-) myeloma cell lines expressed neuronal cell markers, such as neuron-specific enolase and beta-tubulin III. CD7 expression in Liu01 cells and forskolin-stimulated U266 cells coincided with the presence of large cytoplasmic granules, and these cells featured increased expression of perforin messenger RNA and significant natural killer cell activity. Interleukin 6 (IL-6), a growth factor for myeloma cells, down-regulated CD33, CD7, or CD56 expression in primary myeloma cells, as well as in Liu01 cells. Therefore, these data suggest that human myeloma cells are capable of inducing the expression of multilineage markers and that IL-6 can down-regulate such expression.
Liu
Shangqin
S
Laboratory of Cellular Signal Analysis, Graduate School of Medicine, Yamaguchi University, Ube, Japan.
Otsuyama
Ken-ichiro
K
Ma
Zi
Z
Abroun
Saeid
S
Shamsasenjan
Karim
K
Amin
Jakia
J
Asaoku
Hideki
H
Kawano
Michio M
MM
D015703:Antigens, CD / Q000032:analysis* / Q000187:drug effects; D015415:Biomarkers / Q000032:analysis; D045744:Cell Line, Tumor; D019070:Cell Lineage / Q000187:drug effects*; D015536:Down-Regulation / Q000187:drug effects; D006801:Humans; D015850:Interleukin-6 / Q000494:pharmacology*; D009101:Multiple Myeloma / Q000473:pathology*; D014407:Tumor Cells, Cultured
D015703:Antigens, CD; D015415:Biomarkers; D015850:Interleukin-6